A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development

Journal of Pathology

Volumn 233, Issue 3, 2014, Pages 228-237

  Sherman Baust, Cheryl A ^a   Kuhn, Elisabetta ^d   Valle, Blanca L ^d   Shih, Ie Ming ^d   Kurman, Robert J ^d   Wang, Tian Li ^d   Amano, Tomokazu ^a   Ko, Minoru Sh ^a   Miyoshi, Ichiro ^b   Araki, Yoshihiko ^c   Lehrmann, Elin ^a   Zhang, Yongqing ^a   Becker, Kevin G ^a   Morin, Patrice J ^a,d  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

fallopian tube; intraepithelial carcinoma; ovarian cancer; p53; Top2a; transgenic mouse model

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); PROTEIN; PROTEIN P53; PROTEIN TOP2A; UNCLASSIFIED DRUG; VIRUS LARGE T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CANCER MODEL; CARCINOGENESIS; CONTROLLED STUDY; EPITHELIUM; FEMALE; GENE; GENE EXPRESSION; GENETICALLY ENGINEERED MOUSE STRAIN; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; OVARY CARCINOMA; OVGP 1 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA; SIMIAN VIRUS 40; TOP2A GENE; TRANSGENIC MOUSE; UTERINE TUBE; WILD TYPE;

FALLOPIAN TUBE; INTRAEPITHELIAL CARCINOMA; OVARIAN CANCER; P53; TOP2A; TRANSGENIC MOUSE MODEL;

ADENOCARCINOMA; ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FALLOPIAN TUBES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ENGINEERING; GLYCOPROTEINS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84902349728     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4353     Document Type: Article

References (46)

1. Dubeau L., The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol 1999; 72: 437-442.
2. Kurman RJ, Shih Ie M,. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008; 27: 151-160.
3. Medeiros F, Muto MG, Lee Y, et al., The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230-236.
4. Finch A, Shaw P, Rosen B, et al., Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006; 100: 58-64.
5. Kindelberger DW, Lee Y, Miron A, et al., Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-169.
6. Kuhn E, Kurman RJ, Vang R, et al., TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012; 226: 421-426.
7. Lee Y, Miron A, Drapkin R, et al., A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35.
8. Orsulic S, Li Y, Soslow RA, et al., Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002; 1: 53-62.
9. Connolly DC, Bao R, Nikitin AY, et al., Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003; 63: 1389-1397.
10. Flesken-Nikitin A, Choi KC, Eng JP, et al., Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003; 63: 3459-3463.
11. Laviolette LA, Garson K, Macdonald EA, et al., 17β-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology 2010; 151: 929-938.
12. Mullany LK, Fan HY, Liu Z, et al., Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene 2011; 30: 3522-3536.
13. Perets R, Wyant GA, Muto KW, et al., Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 2013; 24: 751-765.
14. Miyoshi I, Takahashi K, Kon Y, et al., Mouse transgenic for murine oviduct-specific glycoprotein promoter-driven simian virus 40 large T-antigen: tumor formation and its hormonal regulation. Mol Reprod Dev 2002; 63: 168-176.
15. Rangel LBA, Agarwal R, D'Souza T, et al., Tight junction proteins Claudin-3 and Claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 2003; 9: 2567-2575.
16. -ΔΔCt method. Methods 2001; 25: 402-408.
17. Ramos-Vara JA,. Technical aspects of immunohistochemistry. Vet Pathol 2005; 42: 405-426.
18. Gleichmann M, Zhang Y, Wood WH, 3rd, et al., Molecular changes in brain aging and Alzheimer's disease are mirrored in experimentally silenced cortical neuron networks. Neurobiol Aging 2012; 33: 205 e201-205, e218.
19. Cheadle C, Vawter MP, Freed WJ, et al., Analysis of microarray data using Z score transformation. J Mol Diagn 2003; 5: 73-81.
20. Sehdev AS, Kurman RJ, Kuhn E, et al., Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol 2010; 23: 844-855.
21. Carlson JW, Miron A, Jarboe EA, et al., Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008; 26: 4160-4165.
22. Jarboe E, Folkins A, Nucci MR, et al., Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008; 27: 1-9.
23. Shaw PA, Rouzbahman M, Pizer ES, et al., Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol 2009; 22: 1133-1138.
24. Folkins AK, Jarboe EA, Saleemuddin A, et al., A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008; 109: 168-173.
25. Brase JC, Schmidt M, Fischbach T, et al., ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 2010; 16: 2391-2401.
26. Park JH, Lin ML, Nishidate T, et al., PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 2006; 66: 9186-9195.
27. Frese KK, Tuveson DA,. Maximizing mouse cancer models. Nat Rev Cancer 2007; 7: 645-658.
28. Kurman RJ, Shih Ie M,. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-443.
29. Mehrad M, Ning G, Chen EY, et al., A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol 2010; 17: 293-302.
30. Brachova P, Thiel KW, Leslie KK,. The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci 2013; 14: 19257-19275.
31. Hashiguchi Y, Tsuda H, Yamamoto K, et al., Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum Pathol 2001; 32: 988-996.
32. Kusume T, Tsuda H, Kawabata M, et al., The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1999; 5: 4152-4157.
33. Laury AR, Perets R, Piao H, et al., A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 2011; 35: 816-826.
34. Jarboe EA, Pizer ES, Miron A, et al., Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol 2009; 22: 345-350.
35. Bowen NJ, Logani S, Dickerson EB, et al., Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol 2007; 104: 331-337.
36. Dinulescu DM, Ince TA, Quade BJ, et al., Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005; 11: 63-70.
37. Wu R, Hendrix-Lucas N, Kuick R, et al., Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/β-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007; 11: 321-333.
38. Clark-Knowles KV, Garson K, Jonkers J, et al., Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res 2007; 313: 133-145.
39. Quinn BA, Brake T, Hua X, et al., Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One 2009; 4: e8404.
40. Szabova L, Yin C, Bupp S, et al., Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res 2012; 72: 4141-4153.
41. Kim J, Coffey DM, Creighton CJ, et al., High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 2012; 109: 3921-3926.
42. Kwon Y, Shin BS, Chung IK,. The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIα by enhancing the rate of ATP hydrolysis. J Biol Chem 2000; 275: 18503-18510.
43. Di Leo A, Gancberg D, Larsimont D, et al., HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8: 1107-1116.
44. Bar JK, Grelewski P, Noga L, et al., The association between the p53/topoisomerase I and p53/ topoisomerase IIα immunophenotypes and the progression of ovarian carcinomas. Adv Clin Exp Med 2012; 21: 35-42.
45. Kucukgoz Gulec U, Gumurdulu D, Guzel AB, et al., Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma. Arch Gynecol Obstet 2013; 289: 393-398.
46. Chekerov R, Klaman I, Zafrakas M, et al., Altered expression pattern of topoisomerase IIα in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia 2006; 8: 38-45.